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????????????
The number of patients with type 2 diabetes 
（T2DM） is increasing rapidly worldwide, affecting an 
estimated 285 million patients in 20101）. This increase 
has also been seen in Japan.  In Japan, the majority of 
7 .2 million people with diabetes mellitus are aged be-
tween 20 and 79, and the number of people with diabe-
tes mellitus will increase to 10 .15 million by 20302,3）. 
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???????
?????????：The incretin hormone glucagon-like peptide 1 （GLP-1） and its analogs, including the gluca-
gon-like peptide 1 receptor agonist liraglutide, use a simple once-daily regimen and can be easily introduced 
in the outpatient setting. We compared treatment with liraglutide monotherapy and dipeptidyl peptidase-4 
（DPP-4） inhibitor monotherapy in patients with untreated type 2 diabetes （T2DM）.
???????：This study included 40 outpatients with untreated T2DM who were randomized to receive li-
raglutide （0.9 mg/day, n＝24） or DPP-4 inhibitors （n＝16：sitagliptin, 50 mg/day） as initial treatment for 
6 months. Glycemic control, urinalysis, blood pressure, body weight, lipid levels, vascular endothelial function, 
and inflammatory factors were assessed before and after treatment.
???????：Significant improvement was observed in HbA1c and fasting blood glucose levels after treatment 
in both groups；improvements in the liraglutide group were significantly better than in the sitagliptin 
group. Only the liraglutide group demonstrated significant improvements in blood pressure, low-density li-
poprotein cholesterol levels, urinary albumin excretion, flow-mediated dilatation, and high-sensitivity C-re-
active protein levels. Linear regression analysis demonstrated a significant negative relation between change 
in flow-mediated dilatation and high-sensitivity C-reactive protein levels.
??????????：Liraglutide provided significant glycemic control and improved blood pressure, lipid levels, 
endothelial function, and inflammatory factors in untreated T2DM. In addition to its impact on blood glucose 
levels, liraglutide may have beneficial effects on the cardiovascular system in patients with T2DM.
???? ????： Type 2 diabetes, Glucagon-like peptide-1 receptor agonist, Liraglutide, Dipeptidyl pepti-
dase-4 （DPP-4） inhibitors, Flow-mediated dilatation
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risk for hypoglycemia when used alone because of its 
glucose level-dependent hypoglycemic action, and un-
like other antidiabetic drugs, is unlikely to cause 
weight gain16,17）. Furthermore, previous studies in cell 
cultures and animal experiments demonstrated that li-
raglutide lowers blood pressure, suppresses arterioscle-
rosis, improves blood lipid profiles, and protects the 
vascular endothelium18〜20）. Similarly, several studies 
have reported the beneficial effects of DPP-4 inhibitors 
on endothelial function in T2DM21,22）. The present 
study was conducted in patients with untreated T2DM 
to compare the effects of liraglutide with DPP-4 inhibi-
tors, in particular, sitagliptin on glycemic control, uri-
nalysis, blood pressure, body weight, lipid levels, vascu-
lar endothelial function, and inflammatory factors 
before and after treatment.
???????
Subjects
Fifty-six outpatients with T2DM who had not re-
ceived any previous treatment for diabetes were en-
rolled. All patients had visited the Department of En-
docrinology and Metabolism at Dokkyo Medical 
University （Tochigi, Japan） between October 2009 and 
August 2012. The other eligibility criteria were as fol-
lows：age＞20 years and hemoglobin A1c （HbA1c）＞
7.5％. Use of medications for hypertension or dyslipid-
emia was permitted. Exclusion criteria were as fol-
lows：type 1 diabetes, severe complication of diabetes, 
severe renal and liver dysfunction, pregnant or nursing 
women and those who might be pregnant, alcoholism, a 
history of stroke and cardiovascular events, and any 
patient whom the investigator judged to be inappropri-
ate for this study.
This study was approved by the Ethics Committee 
of Dokkyo Medical University. All subjects were given 
an explanation of the study and written informed con-
sent was obtained. This study was designed as a pro-
spective, non-blinded study in accordance with the 
principles stated in the Declaration of Helsinki.
Study Design
This study was a randomized, non-blind study, 56 
outpatients were enrolled this study. Of these, 16 pa-
tients withdrew from the study and 40 completed the 
study.  Patients were prospectively assigned to receive 
Antidiabetic pharmacotherapy has progressed signifi-
cantly in recent years, and a variety of therapeutic op-
tions are currently available. In addition to insulin and 
conventional oral antidiabetic agents that have been 
used for many years4 ,5）, several newer antidiabetic 
medications have become available including dipeptidyl 
peptidase-4 （DPP-4） inhibitors and glucagon-like pep-
tide 1 （GLP-1） receptor agonists. These newer drugs 
improve glucose metabolism through the activation of 
GLP-1 receptor signaling, which induces insulin secre-
tion and suppresses glucagon secretion in the pancre-
as6,7）.
T2DM increases the risk of atherosclerosis and car-
diovascular disease. Endothelial dysfunction signals the 
start of the atherosclerotic process8）. Atherosclerosis is 
an inflammatory disease of the arterial walls, and accu-
mulating evidence suggests the involvement of endo-
thelial dysfunction in all stage of atherogenesis 9）. 
Therefore, therapy that reduces inflammatory activity 
and improves endothelial function may have additional 
therapeutic value in the prevention of atherosclerotic 
diseases such as hypertension, hypercholesterolemia, 
and heart failure10）.
Diet and exercise therapy are the first-line treat-
ment for T2DM, but medication to achieve normogly-
cemia is indicated if strict glycemic control cannot be 
achieved. The American Diabetes Association and the 
European Association for the Study of Diabetes have 
issued a consensus algorithm for the treatment of 
T2DM11）, in which biguanides are recommended as 
first-line drug therapy. As recommended in these 
guidelines, the selection of medications for patients 
with T2DM in Japan is dependent on the diverse con-
ditions of individual patients12）. In Japan, oral antidia-
betic agents are often used as the first-line treatment 
for untreated T2DM, sometimes resulting in a compli-
cated regimen of oral medications and poor compliance 
with therapy13,14）. For patients with T2DM who cannot 
be adequately treated with diet and exercise, selecting 
a drug that will ensure good compliance may help lead 
to continued treatment.
Administration of liraglutide can be easily intro-
duced in the outpatient setting compared to multiple 
daily insulin injections or exenatide, another GLP-1 re-
ceptor agonist, which is administered twice daily be-
fore meals15）. Liraglutide is also associated with a low 
212 DJMS
Liraglutide versus Dipeptidyl Peptidase-4 Inhibitors
analyzed by the student paired t test or unpaired t 
test. Differences in non-parametric data were analyzed 
using the Mann-Whitney U-test and Wilcoxon’s 
matched pairs test. We performed linear regression 
analysis to determine the association of each variable 
with change in FMD. Univariate and multivariate logis-
tic regression analysis were used to assess if each clini-
cal marker correlated with an improvement in endo-
thelial dysfunction （DFMD or change in FMD：after 
6 months ％FMD–before treatment ％FMD）. Values of 
p＜0 .05 were considered statistically significant. All 
analyses were performed using Prism 5 （GraphPad 
Software, Inc., San Diego, CA, USA） or Stat mate Ⅴ 
（Nihon 3B Scientific Inc., Niigata, Japan）. 
Results
Table 1 shows baseline characteristics of study sub-
jects；there were no significant differences between 
groups, including the number of patients in each group 
with hypertension, being treated for hypertension, with 
dyslipidemia, and being treated for dyslipidemia. More-
over, there were no significant differences between 
groups in any clinical or biochemical parameter at 
baseline.
After 6 months, HbA1c levels significantly decreased 
in both groups （Table 2）. HbA1c changes in the lira-
glutide group were significantly greater than in the si-
tagliptin group （p＜0.01）. FBG levels also significantly 
decreased in both groups. Changes in FBG levels in the 
liraglutide group were significantly greater than in the 
sitagliptin group （p＜0.01）. CPR index significantly in-
creased in the liraglutide group；there were no signifi-
cant changes in the sitagliptin group.
Significant reductions in systolic blood pressure and 
diastolic blood pressure were observed in the liraglu-
tide group, no significant changes in these variables 
were seen in the sitagliptin group. Similarly, LDL-C 
levels decreased significantly in the liraglutide group, 
whereas no significant changes were seen in the sita-
gliptin group.
Urinary albumin excretion was significantly reduced 
in the liraglutide group, but not in the  sitagliptin 
group. Mean body weight decreased significantly in the 
liraglutide group. Although body weight decreased in 
the sitagliptin group, changes did not reach statistical 
significance. HDL-C, TG, and eGFR levels did not 
treatment with either liraglutide （0.9 mg/day, n＝24） 
or DPP-4 inhibitors, sitagliptin, （n＝16：50 mg/day） 
for 6 months. Our hospital nutritionist educated all pa-
tients regarding dietary habits in accordance with the 
guidelines of the Japan Diabetes Society23）.
The titration schedule for liraglutide and was deter-
mined at the discretion of the investigator. The liraglu-
tide dose was titrated to and maintained at 0.9 mg/day 
within 1 month from study start. All patients were 
evaluated at the start of the study and 6 months after 
starting treatment.
Evaluation of Endothelial Function
Flow-mediated dilatation （FMD） was used to evalu-
ate endothelial function. Monitoring took place in the 
outpatient setting using UNEXEF18G （UNEX, Nagoya, 
Japan）24〜26） after subjects rested for 30 min under fast-
ing conditions. FMD values were calculated using the 
following formula26）：
％FMD＝ （diameter at peak hyperemia–diameter at 
rest）/（diameter at rest）×100.
Other Measurements
Blood and urine samples were collected at baseline 
（before treatment） and at 6 months in the early morn-
ing following an overnight fast. The following variables 
were assessed at the same timepoints：HbA1c level, 
fasting blood glucose （FBG）, high-density lipoprotein 
cholesterol （HDL-C）, low-density lipoprotein cholester-
ol （LDL-C）, triglycerides （TG）, urinary albumin excre-
tion, and high-sensitivity C-reactive protein （hs-CRP）. 
Renal function was determined from the estimated glo-
merular filtration rate （mL/min−1･1.73 m−2）27）. The C-
peptide immunoreactivity （CPR） index was measured 
as a parameter for endogenous insulin secretion28〜30） 
and calculated with the following formula29）：
（Fasting serum CPR （ng/mL）/fasting plasma glu-
cose （mg/dL））×100.
Blood pressure was recorded and body weight was 
measured using a body composition analyzer （InBody 
720；Biospace, Tokyo, Japan）.
Statistical Analysis
Normally distributed parameters are expressed as 
mean ± standard deviation （SD） or as the median and 
interquartile range. Differences between groups were 
??（3） （2014） 213
Kunihiro Suzuki
nificant. The change in ％FMD in the liraglutide group 
was significantly better than in the sitagliptin group （p
＜0.05；Figure 1A）. 
The level of hsCRP significantly decreased from 2.3 
［0.8-3.3］ mg/L to 0.4 ［0.2-1.0］ mg/L （p＜0.01） in the 
change significantly in either group at 6 months.
％FMD significantly improved from 6.4％±1.6％ to 
8.5％±1.9％ in the liraglutide group, while in the sita-
gliptin group, ％ FMD slightly increased from 6.4％±
1.6％ to 6.6％±1.1％. although changes were not sig-
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???????　Baseline characteristics of subjects
Liraglutide （n＝24） Sitagliptin （n＝16） P value
Males/females 15/9 9/7 0.70
Age, yrs 58.6±15.9 56.1±15.3 0.26
Duration of diabetes, yrs 2.4±2.8 1.9±2.3 0.49
Body mass index, kg/m2 　28.2±7.2 　 　26.3±7.2 　 0.39
HbA1c, ％at admission 9.8±2.2 9.1±1.6 0.22
Hypertension, n（％） 12（50.0） 6（37.5） 0.44
Medications for hypertension
　ACEIs or ARBs, n（％） 　 3（12.5）　 3（18.8） 0.59
　CCB, n（％） 　2（8.3）　 2（12.5） 0.67
Dyslipidemia 13（54.1） 6（37.5） 0.30
Statins, n（％） 　1（3.8）　 　0（0.0） 　 0.41
Fibrates, n（％） 　0（0.0）　 　0（0.0） 　 0.99
Current smoking, n（％） 　 8（33.3）　 4（25.0） 0.57
Data are means ±SD.
DPP-4, dipeptidyl peptidase-4；HbA1c, hemoglobin A1c；ACEI, angiotensin-converting 
enzyme inhibitor；ARB, angiotensin Ⅱ receptor blocker；CCB, calcium-channel blocker.
???????　Comparison of clinical and biochemical parameters at baseline and 6 months
Liraglutide（n＝24） Sitagliptin（n＝16）
Baseline 6 Months Baseline 6 Months P1 value P2 value P3 value
HbA1c, ％（NGSP） 9.8±2.2 7.4±1.7 9.1±1.6 8.0±1.4 ＜0.001＊ ＜0.001＊ 0.22
Fasting glucose, mg/dL 216.3±64.5 137.4±36.8 197.8±48.5 162.3±32.6 ＜0.001＊ ＜0.01＊ 0.27
CPR index 1.0±0.4 2.2±1.2 1.5±1.0 1.8±1.0 ＜0.01＊ 0.06 0.34
SBP, mmHg 138.0±20.5 129.5±16.2 136.7±19.3 135.1±17.3 ＜0.01＊ 0.36 0.89
DBP, mmHg 81.6±11.8 74.2±9.5 79.8±10.4 76.8±11.3 ＜0.01＊ 0.20 0.60
LDL-C, mg/dL 137.4±42.3 117.4±32.7 139.3±26.0 140.0±26.4 ＜0.001＊ 0.63 0.83
HDL-C mg/dL 47.1±13.2 47.1±10.9 49.1±11.7 47.2±10.6 0.96 0.15 0.55
TG, mg/dL 173.5±79.5 153.4±54.3 153.1±59.6 155.0±48.0 0.16 0.82 0.3
eGFR, mL・min−1･1.73 m−2 73.2±13.4 72.9±14.4 73.7±12.6 72.6±13.1 0.83 0.33 0.88
Body weight, kg 82.3±19.0 79.3±19.2 81.7±25.4 80.2±25.1 ＜0.01＊ 0.19 0.94
FMD, ％ 6.4±1.6 8.5±1.9 6.4±1.6 6.6±1.1 ＜0.01＊ 0.44 0.90
Urinary albumin excretion, mg/g･Cre 19.0 （9.0−92.75） 9.5 （7.3−60.5） 14.0 （7.1−49.0） 15.0 （9.0−48.0） 0.02＊ 0.87 0.34
hsCRP, mg/L 2.3 （0.8−3.3） 0.4 （0.2−1.0） 1.3 （1.0−2.8） 1.2 （0.1−2.0） ＜0.01＊ 0.05 0.67
Data are mean±SD or median and interquartile range.
CPR, C-peptide immunoreactivity；SBP, systolic blood pressure；DBP, diastolic blood pressure；LDL-C, low-density 
lipoprotein cholesterol；HDL-C, high-density lipoprotein cholesterol；TG, triglycerides；eGER, estimated glomerular filtration 
rate；FMD, flow-mediated dilatation；hsCRP：high-sensitivity C-reactive protein.
＊P1 value：＜0.05, comparison of respective data between baseline and after 6 months with liraglutide.
＊P2 value：＜0.05, comparison of respective data between baseline and after 6 months with Sitagliptin.
　P1 value：＜0.05, comparison of baseline data between liraglutide and Sitagliptin gloups.
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T2DM.
Liraglutide is a GLP-1 analog derived from native 
GLP-1 （7-37） by introducing an arginine substitution 
at position 34 and attaching N-palmitoyl-glutamate to 
the e-amino group of the lysine residue at position 
2631）. Native GLP-1 has a short-lasting action because 
it is rapidly inactivated via enzymatic degradation by 
DPP-4. Liraglutide has several clinically relevant fea-
tures such as a once-daily regimen due to its long ter-
minal half-life of approximately 13 h；its 97％ homoge-
neity to human GLP- 1 , and a lack of elevating 
antibody titers when administered to humans15,32,33）. In 
addition, GLP-1 supplementation is considered impor-
tant because its secretion is generally suppressed in 
T2DM diabetes34）．
Both GLP-1 receptor agonists and DPP-4 inhibitors, 
which are incretin-related drugs, have a protective ef-
fect on pancreatic b-cell dysfunction33 ,35）. Given the 
long-term perspective, pancreatic b-cell dysfunction in 
patients with diabetes might be prevented or delayed 
by relatively early intensive therapy with these drugs. 
Therefore, in Japan, DPP-4 inhibitors are often used as 
first-line treatment for early stage T2DM. In this 
liraglutide group, but did not change significantly in 
the sitagliptin group （1.3 ［1.0-2.8］ mg/L to 1.2 ［0.1-
2.0］ mg/L）. 
According to linear regression analysis, changes in 
hs-CRP （Dhs-CRP） and urinary albumin excretion 
（DU-Alb） were significantly negatively correlated 
with changes in ％FMD in the liraglutide group. （Fig-
ure 1B）. Furthermore, multivariate logistic regression 
analysis identified the decrease of Dhs-CRP due to the 
treatment of liraglutide as a significant and indepen-
dent determinant of improvement in endothelial func-
tion （Table 3）.
??????????
The present study compared the efficacy of liraglu-
tide with DPP-4 inhibitors, in particular, sitagliptin for 
untreated T2DM. Although both agents lead to im-
provements in glycemic control, changes were signifi-
cantly better with liraglutide. In addition, liraglutide 
provided significantly better improvement in peripher-
al endothelial dysfunction compared with DPP-4 inhibi-
tors. This is the first report that compares treatment 
with liraglutide with DPP-4 inhibitors for untreated 
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????????　 Change in flow-mediated dilatation （FMD）：Univariate analysis for 
improvement in endothelial function. ?） Change in FMD after 6 months. ?） 
Correlation between changes in FMD and changes in high-sensitive 
C-reactive protein （hs-CRP） and urinary albumin excretion （U-Alb 
excretion）. Linear regression analysis demonstrated a significant correlation 
in liraglutide group between changes in ％ FMD and hs-CRP （r＝−0.70, p＜
0.001）, urinary albumin excretion （DU-Alb excretion） （r＝0.69, p＜0.001）.
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tion in all stages of atherosclerosis38,39）. DeFronzo et al. 
reported that a GLP-1 receptor agonist enhanced 
GLP-1 concentration after 2 weeks administration 
（15.1 pM vs. 63 .8 pM）40） compared DPP-4 inhibitors. 
The effect of GLP-1 receptor agonists and DPP-4 in-
hibitors on endothelial function could reflect increased 
phosphorylation of endothelial nitric oxidase synthase 
（eNOS）20,40）. Nitric oxide, produced by eNOS, plays an 
important role in vascular homeostasis, coordination of 
endothelial cell function via GLP-1 receptors, and athe-
roprotective effects41）. Although we could not measure 
active GLP-1 levels in this study, the effect of DPP-4 
inhibitors in this area might be weaker than that ex-
hibited by GLP-1 receptor agonists. Gaspari et al. re-
ported that liraglutide improved endothelial function 
via GLP-1 receptors, increased eNOS levels, and re-
duced ICAM-1 expression in the aortic endothelium in 
mice42）. On the other hand, Hopkins et al. reported that 
exedin-4 and liraglutide did not improve the FMD re-
sponse in obese patients with T2DM43）. These findings 
remain controversial because none of the studies that 
showed that GLP-1 receptor agonists improved endo-
study, HbA1c and FBG levels showed significantly 
greater improvement in the liraglutide treatment 
group compared with the DPP-4 inhibitors group. 
These data showed greater glycemic improvement 
than what was reported in the LEAD3 trial （approxi-
mately 1 .1％ reduction after 52 weeks of treatment 
with 1 .8 mg liraglutide）36） and a domestic phase III 
clinical trial （1.74％ reduction after 24 weeks of treat-
ment with 0.9 mg liraglutide）37）. The favorable results 
in our study may be attributed to differences in patient 
populations；our study included patients with untreat-
ed T2DM, and the proportion of obese patients was 
high in this study.
While the LEAD3 trial only reported a significant 
reduction in systolic blood pressure36）, our study dem-
onstrated significant improvements in both systolic and 
diastolic blood pressure. Although these effects could 
be due to weight reduction, we also evaluated vascular 
endothelial function by FMD, which showed a greater 
improvement of ％ FMD than what was reported with 
DPP-4 inhibitor monotherapy21）. Accumulating evi-
dence supports the involvement of endothelial dysfunc-
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???????　 Univariate and multivariate analysis for association with each variable 
with improvement endothelial function
Variable
Univariate Multivariate
r P value b P value
Age, yrs −0.18 0.23 ─ ─
Sex −0.12 0.43 ─ ─
DHbA1c, per％ −0.22 0.14 ─ ─
DFasting glucose per mg/dL −0.432 ＜0.05 −0.01 0.88
DCPR index 0.22 0.13 ─ ─
DSBP, per mmHg −0.44 ＜0.01 −0.03 0.23
DDBP, per mmHg −0.25 0.13 ─ ─
TC
DLDL-C, per mg/dL −0.5 ＜0.001 −0.13 0.45
DHDL-C, per mg/dL 0.01 0.96 ─ ─
DTG, per mg/dlL −0.07 0.63 ─ ─
DeGFR, per mL･min−1･1.73 m−2 −0.23 0.18 ─ ─
DBody weight, per kg −0.08 0.59 ─ ─
DhsCRP, per mg/L −0.7 ＜0.001 −5.56 0.01
DUrinary albumin excretion −0.69 ＜0.001
R2　　 　0.64
HbA1c, hemoglobin A1c；CPR, C-peptide immunoreactivity；SBP, systolic 
blood pressure；DBP, diastolic blood pressure；DBP, diastolic blood pressure；
LDL-C, low-density lipoprotein cholesterol；TC, total cholesterol；HDL-C, 
high-density lipoprotein cholesterol；TG, triglycerides；eGER, estimated 
glomerular filtration rate；hsCRP, high-sensitivity C-reactive protein.
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itors are weight neutral. Recently, it was shown that 
chronic stimulation of GLP-1 receptor leads to desensi-
tization of gastric inhibitory effects, and the effects of 
liraglutide on gastric emptying were markedly reduced 
following 14 days of dosing49）；similar findings were 
seen in an acute study by Nauck et al50）. However, we 
do not believe that gastric emptying is responsible for 
the long-term reductions in body weight seen with li-
raglutide. Jelsing et al. reported that chronic GLP-1 
receptor exposure by liraglutide is needed to desensi-
tize the gastric inhibitory effects of GLP-1 receptor 
agonists and that gastric inhibition did not contribute 
to weight loss. Body weight loss elicited by liraglutide 
is thought to be mediated by either brainstem or hypo-
thalamic GLP-1 receptors49）. Our results indicate that, 
at least, that body weight loss induced by liraglutide 
continued for 6 months.
This study has several limitations. First, this  was a 
randomized, non-blind study. However the characteris-
tics of patients were well matched between groups. 
Second, the number of subjects enrolled was relatively 
small. We expect that large-scale, randomized, pro-
spective, clinical studies will provide more concrete ev-
idence of whether incretin therapy provides clinical 
benefits of vascular protection for patients with T2DM. 
Third, we did not assess levels of GLP-1 and oxidative 
stress factors. Fourth, it should be noted that the maxi-
mum dosage of liraglutide used in Japan （0.9 mg/day） 
is much lower than that used in western countries. 
Further studies are needed to determine the correla-
tion between changes in endothelial function and 
changes in active GLP-1, glucose-dependent insulino-
tropic polypeptide （GIP）, and oxidative stress.
??????????
We compared the efficacy and benefit of liraglutide 
with DPP-4 inhibitors, sitagliptin, in patients with ear-
ly-stage, untreated T2DM. Our results indicate that li-
raglutide could provide additional benefits to blood 
glucose lowering, subsequently protecting against vas-
cular endothelial dysfunction.
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thelial function were randomized trials. However, sub-
jects in the present study were all untreated and 
drug-naive patients with type 2 diabetes, which is 
similar to subjects included in GLP-1 receptor clinical 
trials, and this might have influenced our findings re-
garding the protective effects of liraglutide on endothe-
lial function.
Specific effects of DPP-4 inhibitors on endothelial 
function could occur within other substrates of DPP-4. 
Inhibition of DPP-4 enzymatic activity could also mod-
ulate the activity of several proteins, such as stromal 
cell-derived factor-1 alpha, which stimulates bone mar-
row mobilization of endothelial cells and brain natri-
uretic peptide. DPP-4 inhibition may repair endothelial 
cells and improve cardiovascular function, thus result-
ing in an indirect improvement of endothelial func-
tion44）. These results suggest that DPP-4 inhibitors 
improve endothelial function by increasing the number 
of endothelial cells through augmentation of stromal 
cell-derived factor-1 alpha. Although we could not 
demonstrate the effect of DPP-4 inhibitors on endothe-
lial function in the present study, we believe that this is 
an interesting hypothesis for future study.
We also observed a significant improvement in the 
hs-CRP and urinary albumin excretion. Although 
GLP-1 exerts its effects on the vessels through nitric 
oxide-mediated action45） as well as via direct action46）, 
what we observed is likely due to direct anti-inflam-
matory actions that can preserve endothelial dysfunc-
tion and inhibit diabetic complications. In terms of 
blood lipid profiles, we observed a significant reduction 
in LDL-C levels but not in TG or HDL-C levels after 
liraglutide treatment. However, GLP-1 receptor ago-
nists have been reported to reduce TG levels 47）, and 
further evaluation of the effect on TG in a larger popu-
lation is required.
The body weight of patients in the DPP-4 inhibitors 
group did change significantly before and after treat-
ment, but in the liraglutide group, body weight signifi-
cantly decreased. The underlying mechanisms of lira-
glutide that mediate weight loss are not clear, but it is 
a general belief that it is likely a combination of effects 
on the gastrointestinal tract and central GLP-1 recep-
tor expressing neurons48）. It is generally accepted that 
GLP-1 receptor agonists increase satiety, reduce food 
intake, and promote weight loss, whereas DPP-4 inhib-
??（3） （2014） 217
Kunihiro Suzuki
???：713-727, 2009.
 11） Inzucchi SE, Bergenstal RM, Buse JB, et al：Manage-
ment of hyperglycemia in type 2 diabetes：A patient- 
centered approach：position statement of the Ameri-
can Diabetes Association （ADA） and the European 
Association for the study of Diabetes （EASD）. Diabe-
tes Care ??：1364-1379, 2012.
 12） Treatment Guide for diabetes 2012-2013, Japan Dia-
betes Society, Bunkodo, P 17-18.
 13） Yoshioka N, Ishii H, Tajima N, et al：Curr Med Res 
Opin ??：177-183, 2013.
 14） Hertz RP, Unger AN, Lustik MB：Adherence with 
pharmacotherapy for type 2 diabetes：a retrospective 
cohort study of adults with employer-sponsored 
health insurance. Clin Ther ??：1064-1073, 2005.
 15） Buse JB, Rosenstock J, Sesti G, et al：Liraglutide once 
a day versus exenatide twice a day for type 2 diabe-
tes：a 26-week randomised, parallel-group, multina-
tional, open-label trial （LEAD-6）. Lancet ???：39-47, 
2009.
 16） Drucker DJ, Sherman SI, Gprelick FS, et al：Incretin 
based therapies for the treatment of type 2 diabetes：
evaluation of the risks and benefits. Diabetes Care 
??：428-433, 2010.
 17） Astrup A, Carraro R, Finer N, et al：Safety, tolerabili-
ty and sustained weight loss over 2 years with the 
once-daily human GLP-1 analog, liraglutide. Int Obes 
（Lond） ??：843-854, 2012.
 18） Liu H, Dear AE, Knudsen LB, et al：A long-acting 
glucagon-like peptide-1 analogue attenuates induc-
tion of plasminogen activator inhibitor type-1 and 
vascular adhesion molecules. J Endocrinol ???：59-
66, 2009.
 19） Arakawa M, Mita T, Azuma K, et al：Inhibition of 
monocyte adhesion to endothelial cells and attenua-
tion of atherosclerotic lesion by a glucagon-like pep-
tide-1 receptor agonist, exendin-4 . Diabetes ??：
1030-1037, 2010.
 20） Han L, Yu Y, Wang B：Exendin-4 directly improves 
endothelial dysfunction in isolated aortas from obese 
rats through the cAMP or AMPK-eNOS pathways. 
Diabetes Res Clin Pract ??：453-460, 2012.
 21） van Poppel PC, Netea MG, Smits P, et al：Vildagliptin 
improves endothelium-dependent vasodilatation in 
type 2 diabetes. Diabetes Care ??：2072-2077, 2011.
 22） Matsubara J, Sugiyama S, Akiyama E, et al：Dipepti-
the Japan Translation Federation provided assistance 
with English language editing and preparation of the 
manuscript for submission.
Conflicts of Interest　Kunihiro Suzuki, Seiich Tanaka, 
Chie Aoki, Kanako Kato, Teruo Jojima and Yoshimasa 
Aso declare that they have no conflicts of interest. No 
funding was received for this study or publication of 
this article.
??????????
 1） Shaw JE, Sicree RA, Zimmet PZ：Global estimates of 
the prevalence of diabetes for 2010 and 2030. Diabe-
tes Res Clin Pract ??：4-14, 2010.
 2） Whiting DR, Guariguata L, Weil C, Shaw J：IDF dia-
betes atlas：global estimates of the prevalence of dia-
betes for 2011 and 2030. Diabetes Res Clin Pract ??：
311-321, 2011.
 3） Guariguata L：By the numbers：new estimates from 
the IDF Diabetes Atlas Update for 2012. Diabetes Res 
Clin Pract ??：524-525, 2012.
 4） de Heer J, Rasmussen C, Coy DH, et al：Glucagon-
like peptide-1, but not glucose-dependent insulinotro-
pic peptide, inhibits glucagon secretion via somatosta-
tin （receptor subtype 2） in the perfused rat pancreas. 
Diabetologia ??：2263-2270, 2008.
 5） Balas B, Baig MR, Watson C, et al：The dipeptidyl 
peptidase IV inhibitor vildagliptin suppresses endoge-
nous glucose production and enhances islet function 
after single-dose administration in type 2 diabetic pa-
tients. J Clin Endocrinol Metab ??：1249-1255, 2007.
 6） Drucker DJ, Nauck MA：The incretin system：gluca-
gon-like peptide-1 receptor agonist and dipeptidyl 
peptidase-4 inhibitors in type 2 diabetes. Lancet 
???：1696-1705, 2006.
 7） Kolterman OG, Buse JB, Fineman MS, et al：Synthet-
ic exedin-4 （exenatide） significantly reduces post-
prandial and fasting plasma glucose in subject with 
type 2 diabetes. J Clin Endocrinol Metab ??：3082-
3089, 2003.
 8） Davignon J, Ganz P：Role of endothelial dysfunction 
in atherosclerosis. Circulation ???：27-32, 2004.
 9） Libby P：Inflammation in atherosclerosis. Nature 
???：868-874, 2002.
 10） Szabo C：Role of nitrosative stress in the pathgenesis 
of diabetic vascular dysfunction. Br J Pharmacol 
218 DJMS
Liraglutide versus Dipeptidyl Peptidase-4 Inhibitors
Res Commun ???：577-584, 2005.
 34） Vilsbøll T, Krarup T, Deacon CF, et al：Reduced 
postprandial concentrations of intact biologically ac-
tive glucagon-like peptide 1 in type 2 diabetic pa-
tients. Diabetes ??：609-613, 2001.
 35） Xu L, Man CD, Charbonnel B, et al：Effect of sita-
gliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell 
function in patients with type 2 diabetes：a model-
based approach. Diabetes Obes Metab ??：1212-
1220, 2008.
 36） Gabor A, Henry R, Ratner R：Liraglutide versus 
glimepiride monotherapy for type 2 diabetes （LEAD-
3 Mono）：a randomised, 52-week, phase III, double-
blind, parallel-treatment trial. Lancet ???：473-481, 
2009.
 37） Seino Y, Rasmussen MF, Nishida T, et al：Efficacy 
and safety of the once-daily human GLP-1 analogue, 
liraglutide, vs glibenclamide monotherapy in Japanese 
patients with type 2 diabetes. Curr Med Res Opin 
??：1013-1022, 2010.
 38） van Poppel PC, Netea MG, Smits P, et al：Vilda-
gluptin improves endothelium-dependent vasodilata-
tion in type 2 diabetes. Diabetes Care ??：2072-2077, 
2011.
 39） Vita JA, Keaney JF Jr：Endothelial function：a ba-
rometer for cardiovascular risk. Circulation ?：640-
642, 2002.
 40） DeFronzo RA, Okerson T, Viswanathan P, et al：Ef-
fect of exenatide versus sitagliptin on postprandial 
glucose, insulin and glucagon secretion, gastric empty-
ing  and caloric intake：a randomized, cross-over 
study. Curr Med Res Opin ??：2943-2952, 2008.
 41） Shah Z, Pineda C, Kampfrath T, et al：Acute DPP-4 
inhibition modulates vascular tone through GLP-1 in-
dependent pathways. Vascul Pharmacol ??：2-9 , 
2011.
 42） Gaspari T, Liu H, Welungoda I, et al：A GLP-1 recep-
tor agonist liraglutide inhibits endothelial cell dysfunc-
tion and vascular adhesion molecule expression in an 
ApoE-/- mouse model. Diab Vasc Dis Res ?：117-
124, 2011.
 43） Hopkins ND, Cuthbertson DJ, Kemp GJ, et al：Effects 
of 6 months glucagon-like peptide-1 receptor agonist 
treatment on endothelial function in type 2 diabetes 
mellitus patients. Diabetes Obes Metab ??：770-773, 
2013.
dyl peptidase-4 inhibitor, sitagliptin, improves endo-
thelial dysfunction in association with its anti-inflam-
matory effects in patients with coronary artery 
disease and uncontrolled diabetes. Circ J ??：1337-
1344, 2013.
 23） Treatment Guide for diabetes 2012-2013, Japan Dia-
betes Society, Bunkodo, P 25-26.
 24） Voidonikola PT, Stamatelopoulos KS, Alevizaki M, et 
al：The association between glycemia and endothelial 
function in nondiabetic individuals：the importance of 
body weight. Obesity ??：2658-2662, 2008.
 25） Nochioka K, Tanaka S, Miura M, et al：Ezetimibe im-
proves endothelial function and Rho-kinase activity 
associated with inhibition of cholesterol absorption in 
humans. Circ J ??：2023-2030, 2012.
 26） Corretti MC, Anderson TJ, Benjamin EJ, et al：Guide-
lines for the ultrasound assessment of endothelial-de-
pendent flow-mediated vasodilation of the brachial ar-
tery：a report of the International Brachial Artery 
Reactivity Task Force. J Am Coll Cardiol ??：257-
265, 2002.
 27） Matsuo S, Imai E, Horio M, et al：Revised equations 
for estimated GFR from serum creatinine in Japan. 
Am J Kidney Dis ??：982-992, 2009.
 28） Meier JJ, Menge BA, Breuer TG, et al：Functional as-
sessment of pancreatic beta-cell area in humans. Dia-
betes ??：1595-1603, 2009.
 29） Saisho Y, Kou K, Tanaka K, et al：Postprandial serum 
C-peptide to plasma glucose ratio as a predictor of 
subsequent insulin treatment in patients with type 2 
diabetes. Endocr J ?：315-322, 2011.
 30） Okuno Y, Komada H, Sakaguchi K, et al：Postprandi-
al serum C-peptide to plasma glucose concentration 
ratio correlates with oral glucose tolerance test- and 
glucose clamp-based disposition indexes. Metabolism 
??：1470-1476, 2013.
 31） Knudsen LB：Glucagon-like peptide-1：the basis of a 
new class of treatment for type 2 diabetes. J Med 
Chem ??：4128-4134, 2004.
 32） Rollin B, Larsen MO, Gotfredsen CF, et al：The long-
acting GLP-1 derivate NN2211 ameliorates glycemia 
and increases beta-cell mass in diabetic mice. Am J 
Physiol Endocrino Metab ???：E745-752, 2002.
 33） Bregenholt S, Møldrup A, Blume N, et al：The long-
acting glucagon-like peptide-1 analogue, liraglutide, 
inhibits beta-cell apoptosis in vitro. Biochem Byophys 
??（3） （2014） 219
Kunihiro Suzuki
alog, given as monotherapy significantly improves 
glycemic control and lower body weight without risk 
of hypoglycemia in patients with type 2 diabetes. Dia-
betes Care ??：1608-1610, 2007.
 48） Jelsing J, Vrang N, Hansen G, et al：Liraglutide：
short-lived effect on gastric emptying ─ long lasting 
effects on body weight. Diabetes Obes Metab ??：
531-538, 2012.
 49） Nauck MA, Kemmeries G, Holst JJ, et al：Rapid 
tachyphylaxis of the glucagon-like peptide 1-induced 
deceleration of gastric emptying in humans. Diabetes 
??：1561-1565, 2011.
 44） Fadini GP, Agostini C, Sartore S, et al：Endothelial 
progenitor cells in the natural history of atherosclero-
sis. Atherosclerosis ???：46-54, 2007.
 45） Golpon HA, Puechner A, Welte T, et al：Vasorelaxant 
effect of glucagon-like peptide-（7-36）amide and am-
ylin on the pulmonary circulation of the rat. Regul 
Pept ???：81-86, 2003.
 46） Ozyazgan S, Kutluata N, Afsar S, et al：Effect of glu-
cagon-like peptide-1（7-36） and exendin-4 on the 
vascular reactivity in streptozotocin/nicotinamide dia-
betic rats. Pharmacology ??：119-126, 2005.
 47） Vilsbøll T, Zdravkovic M, Le-Thi T, et al：Liraglu-
tide, a long-acting human glucagon-like peptide-1 an-
220 DJMS
